Healius Limited (ASX: HLS) disclosed the successful completion of the sale of Montserrat Day Hospitals (Montserrat) to Nexus Hospitals. Healius has received cash proceeds totalling AU$127 million, representing an enterprise value of AU$138.6 million after deferred contingent consideration and completion adjustments, which consider working capital, debt, and debt-like factors, as well as completion adjustments. The sale price is almost 18 times the adjusted EBITDA for FY22. About the gearing ratio covenant for the 30 June 2023 and 31 December 2023 testing dates, Healius has obtained the backing of its banking syndicate.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 22, 2024
Oct 21, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
